Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide

Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. Insulin delivery and diabetes medical device mak...
Streetwise Reports | August 6, 2019 |

GlucoTrack: Company Addresses the Diabetes Testing and Monitoring Conundrum

GlucoTrack ( NDAQ:GCTK ) is an American medical device company focused on design, development and commercialization. The company is developing proprietary painless and non-invasive blood glucose monitoring devices for both Type 2 diabetes and prediabetes, a market almost ...
Simon Druker | January 16, 2023 |

vTv Therapeutics' Shares open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. Clinical-stage pharmaceutical company focused on treating ...
Streetwise Reports | February 11, 2020 |

Buzz on the Bullboards: Creating Cash out of an Economy Crunch

(Image via Bombardier Inc.) If you’re looking to see the stocks that investors have been keeping an eye on over the past week, you’ve come to the right place. The Stockhouse community regularly acts as a microcosm of investor sen...
Stockhouse Editorial | May 25, 2022 |

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. Yesterday afternoon, The Woodlands, Tex.-based Lexicon Pharmaceu...
Streetwise Reports | September 12, 2019 |

Buzz on the Bullboards: Early Movers in Health, Mining and Tech

By the second week of the year, people, businesses and even the stock market are back to business as usual following the holiday rush in December and ringing in the new year in early January. Discussions on our Stockhouse Bullboards are also back in the saddle, and co...
Stockhouse Editorial | January 12, 2022 |

Precious Metals Hit Resistance

The precious metals sector may have begun a correction on Wednesday. The miners (GDX, GDXJ) sold off after reaching significant resistance levels while the metals are trading just below significant resistance levels. We mentioned these targets in our article last wee...
Jordan Roy-Byrne, CMT | May 22, 2020 |

Precious Metals Encounter Long-Term Resistance

A few weeks ago we wrote that precious metals were at risk of a correction. First, they powered higher. But last week they ran into technical resistance levels that date back well beyond only a few years. This is true for Gold, Silver as well as the miner ETFs: GDX and...
Jordan Roy-Byrne, CMT | September 3, 2019 |

Dexcom Posts 49% YoY Revenue Growth, Sending Shares to 52-Week High

Glucose monitoring systems developer Dexcom's shares traded 30% higher today after releasing Q3/19 earnings and raising full-year 2019 guidance. Glucose monitoring systems maker Dexcom Inc. (DXCM:NASDAQ) yesterday announced financial results for its third quarter ...
Streetwise Reports | November 8, 2019 |

Horizon Therapeutics Shares Rise 15% on Strong Q1 Results and Raised F/Y Sales Guidance

Shares of Horizon Therapeutics traded higher setting a new 52-week high price after the company reported a 27% y-o-y increase in net sales for Q1/20 and raised FY/20 net sales guidance. Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ) , whi...
Streetwise Reports | May 7, 2020 |
1 2 3 4 5 6 7 8 9 10 ...